Ikena Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IKENA ONCOLOGY, INC. | ||
| Date: March 12, 2024 | By: | /s/ Mark Manfredi |
|---|---|---|
| Mark Manfredi, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Mark Manfredi | President, Chief Executive Officer and Director | March 12, 2024 |
| Mark Manfredi, Ph.D. | Principal Executive Officer | |
| /s/ Jotin Marango | Chief Financial Officer and Head of Corporate Development | March 12, 2024 |
| Jotin Marango, M.D., Ph.D. | Principal Financial Officer and Principal Accounting Officer | |
| /s/ Owen Hughes | Director | March 12, 2024 |
| Owen Hughes | ||
| /s/ David Bonita | Director | March 12, 2024 |
| David Bonita, M.D. | ||
| /s/ Iain D. Dukes | Director | March 12, 2024 |
| Iain D. Dukes, D.Phil. | ||
| /s/ Jean-François Formela | Director | March 12, 2024 |
| Jean-François Formela, M.D. | ||
| /s/ Maria Koehler | Director | March 12, 2024 |
| Maria Koehler, M.D., Ph.D. | ||
| /s/ Otello Stampacchia | Director | March 12, 2024 |
| Otello Stampacchia, Ph.D. | ||
| /s/ Richard WoosterRichard Wooster, Ph.D. | Director | March 12, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.